Financing soon? March 8, 2022
To: British Columbia Securities Commission, as principal regulator Alberta Securities Commission
Ontario Securities Commission
Xortx Therapeutics Inc. (the "Issuer") intends to be qualified to file a short form prospectus under NI 44-101. The Issuer acknowledges that it must satisfy all applicable qualification criteria prior to filing a preliminary short form prospectus. This notice does not evidence the Issuer's intent to file a short form prospectus, to enter into any particular financing or transaction or to become a reporting issuer in any jurisdiction. This notice will remain in effect until withdrawn by the Issuer.
XORTX THERAPEUTICS INC.
By: (signed) “Allen Davidoff” Name: Allen Davidoff Title: President and CEO